Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Non-randomized, Open-label Dose Escalation Phase Ib Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma (HCC) With no Prior Systemic Therapy

Trial Profile

A Multicenter, Non-randomized, Open-label Dose Escalation Phase Ib Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma (HCC) With no Prior Systemic Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Regorafenib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 13 Nov 2018 Planned End Date changed from 15 Oct 2020 to 17 Feb 2021.
    • 09 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 07 Jun 2018 Planned initiation date changed from 15 May 2018 to 18 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top